Personalized Medicine News and Research

RSS

Viewpoints: Urgency has slipped away for 'grand bargain'; The need to scrutinize drug competition; Restore funding to 'Meals on Wheels'

It may seem paradoxical that Congress was willing to tackle a grand bargain when the deficit problem looked big and insoluble - but quickly lost interest as soon as the problem became more manageable. … But the reason isn't really mysterious. A grand bargain would have required both sides to swallow unpalatable compromises. It would have required Democrats to agree to cuts in future spending on Medicare and Social Security. Likewise, it would have required Republicans to accept increases in tax revenue (Doyle McManus, 6/19).

20 Jun 2013

New breakthrough in chemical nanoengineering may help develop light-regulated therapeutic molecules

The scientific cooperation between chemists, biotechnologists and physicists from various Catalan institutes, headed by Pau Gorostiza, from the Institute for Bioengineering of Catalonia (IBEC), and Ernest Giralt, from the Institute for Research in Biomedicine (IRB Barcelona), has led to a breakthrough that will favor the development of light-regulated therapeutic molecules.

19 Jun 2013

SAP and TUM decode human proteome and provide data for biomedical research

As personalized medicine is on the rise, the healthcare field is discovering the opportunities of "big data" analysis. The result of a joint project between the TUM Chair of Proteomics and Bioanalytics, SAP and the SAP Innovation Center, ProteomicsDB, is a major step forward in human proteomics.

12 Jun 2013

Prostate cancer and DNA: an interview with Dr. Jianfeng Xu, Wake Forest School of Medicine

Prostate cancer development is associated with both inherited and acquired genetic alterations. More than 70 inherited genetic variants have been consistently identified in human DNA that may contribute to susceptibility or risk of prostate cancer.

11 Jun 2013

Diagnoplex secures 1.3 million Swiss francs from financing round

Diagnoplex SA, a developer of molecular diagnostics for colon cancer and Debiopharm Diagnostics SA, part of the Swiss-based global biopharmaceutical group of companies Debiopharm Group™, with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that Diagnoplex has secured 1.3 million Swiss francs from a financing round led by Debiopharm.

7 Jun 2013

Study shows success in pinpointing individualized treatment for women with metastatic breast cancer

Funded by volleyball tournaments, a new study released this week shows success in pinpointing individualized treatment for women with metastatic breast cancer, according to George Mason University researchers.

6 Jun 2013

NJIT professor emphasizes how point of care healthcare can reduce illness, improve quality of life

NJIT Distinguished Professor and electrical engineer Atam Dhawan hits the lecture trail again this summer as a distinguished speaker for an IEEE life sciences lecture series.

3 Jun 2013

Study shows utility of cfDNA blood tests for breast cancer patients

Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center today announced that results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients are to be reported in a poster presentation titled "Modulation of breast cancer cell-free DNA with surgical resection" (Abstract #11060) at the American Society of Clinical Oncology Annual Meeting (ASCO 2013) being held from May 31 through June 4, 2013 in Chicago. The blood test detects cfDNA that is released into the blood stream by damaged and dying cancer cells.

1 Jun 2013

Study supports future possibility of personalized medicine for cervical cancer

Doctors at Washington University School of Medicine in St. Louis have shown that testing cervical tumors before treatment for vulnerability to chemotherapy predicts whether patients will do well or poorly with standard treatment.

1 Jun 2013

New Translational Proteomics journal launched by Elsevier

Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce the launch of Translational Proteomics, an online-only, open access journal devoted to transferring fundamental discoveries in the field of proteomics to clinical applications, accelerating understanding and treatment of human diseases.

28 May 2013

Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates

Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.

23 May 2013

Mayo Clinic, Cancer Genetics form joint venture to improve cancer care

Mayo Clinic and Cancer Genetics Inc. today launched OncoSpire Genomics, a joint venture with the singular goal of improving cancer care by discovering and commercializing diagnostic tests that leverage next-generation sequencing.

23 May 2013

Researchers develop new method for delivering molecules into targeted single cells through temporary holes

Northwestern University researchers have developed a new method for delivering molecules into single, targeted cells through temporary holes in the cell surface. The technique could find applications in drug delivery, cell therapy, and related biological fields.

22 May 2013

GfK to deliver major presentation on personalized medicine at PBIRG Annual General Meeting

GfK will deliver a major presentation about patient perspectives' on personalized medicine at the Pharmaceutical Business and Intelligence Research Group Annual General Meeting, taking place May 19 to 22 in Naples, Florida.

17 May 2013

Weekend reading: Volunteers in the battle with heart disease; Psychiatry without medication; Owning your genes

Psychiatrists who take time with their patients are not the norm. It's not because others don't care. Rather the system rewards efficiency, not empathy.

17 May 2013

Researchers identify clue to explain the reversible memory loss caused by statins

The U.S. Food and Drug Administration and physicians continue to document that some patients experience fuzzy thinking and memory loss while taking statins, a class of global top-selling cholesterol-lowering drugs.

13 May 2013

ALS-ETF, Denovo partner to explore personalized medicine approach for ALS

The ALS Emergency Treatment Fund and Denovo Biomarkers have announced a partnership to explore using Denovo's technology to identify potential responder groups for drugs being studied in ALS patients.

10 May 2013

New research from Wake Forest Baptist looks at gene expression profiling in breast cancer

Predicting outcomes for cancer patients based on tumor-immune system interactions is an emerging clinical approach, and new research from Wake Forest Baptist Medical Center is advancing the field when it comes to the most deadly types of breast cancer.

10 May 2013

Precision Therapeutics to present clinical data of ChemoFx chemoresponse assay at WAGO meeting

Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists.

9 May 2013

Exosome Diagnostics' urine exosome technology accurately predicts outcome of prostate biopsy

Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic products for use in personalized medicine research and clinical diagnostics, today announced the presentation of data at the American Urological Association Annual Meeting in San Diego demonstrating the performance of urine exosome technology in accurately predicting the outcome of a prostate biopsy.

9 May 2013

Personalized Medicine News and Research

Viewpoints: Urgency has slipped away for 'grand bargain'; The need to scrutinize drug competition; Restore funding to 'Meals on Wheels'

New breakthrough in chemical nanoengineering may help develop light-regulated therapeutic molecules

SAP and TUM decode human proteome and provide data for biomedical research

Prostate cancer and DNA: an interview with Dr. Jianfeng Xu, Wake Forest School of Medicine

Diagnoplex secures 1.3 million Swiss francs from financing round

Study shows success in pinpointing individualized treatment for women with metastatic breast cancer

NJIT professor emphasizes how point of care healthcare can reduce illness, improve quality of life

Study shows utility of cfDNA blood tests for breast cancer patients

Study supports future possibility of personalized medicine for cervical cancer

New Translational Proteomics journal launched by Elsevier

Cenix BioScience, Debiopharm partner to develop novel therapeutic drug candidates

Mayo Clinic, Cancer Genetics form joint venture to improve cancer care

Researchers develop new method for delivering molecules into targeted single cells through temporary holes

GfK to deliver major presentation on personalized medicine at PBIRG Annual General Meeting

Weekend reading: Volunteers in the battle with heart disease; Psychiatry without medication; Owning your genes

Researchers identify clue to explain the reversible memory loss caused by statins

ALS-ETF, Denovo partner to explore personalized medicine approach for ALS

New research from Wake Forest Baptist looks at gene expression profiling in breast cancer

Precision Therapeutics to present clinical data of ChemoFx chemoresponse assay at WAGO meeting

Exosome Diagnostics' urine exosome technology accurately predicts outcome of prostate biopsy

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News